Session information

Symposium

[SY10] Symposium 10　Recent advance of systemic therapy for unresectable hepatocellular carcinoma
【E】

Thu. Feb 17, 2022 4:20 PM - 5:50 PM Room 9 (Swan, 1F, Kyoto International Conference Center)

Chair：Junji Furuse（Department of Medical Oncology, Kyorin University Faculty of Medicine），Masafumi Ikeda（Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East）

+Add all to schedule

[SY10-1] Role of lenvatinib and tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in era of immunotherapy

^○Takeshi Terashima (Department of Gastroenterology, Kanazawa University Hospital)

[SY10-2] Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice

^○Kazushi Numata¹, Makoto Chuma¹, Shin Maeda² (1.Yokohama City University Medical Center, 2.Division of Gastroenterology, Yokohama City University Graduate School of Medicine)

[SY10-3] Systemic therapy for HCC in Asia

^○Stephen Lam Chan (Department of Clinical Oncology, The Chinese University of Hong Kong)

[SY10-4] Current status of systemic therapy for uHCC in Korea

^○Changhoon Yoo (Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine)

[SY10-5] Future perspectives of systemic therapy for hepatocellular carcinoma

^○Masafumi Ikeda (Department of Hepatobiliary & Pancreatic Oncology, National Cancer Center Hospital East)

▲